Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Cancer Immunotherapy

Posts tagged ‘PIONEER’

The theme of this year’s ESMO20 virtual meeting was “Bringing innovation to cancer patients,” one that definitely resonates at BSB where our focus is very much on “Bringing innovative science to life.”

In this latest post, we’re taking a closer look at data presented at ESMO20 by Prof Fabrice Barlesi (@Barlesi) on the first 100 patients enrolled in the biomarker part of the PIONeeR Project : Precision Immuno-Oncology for advanced Non-Small Cell Lung Cancer Patients with PD1(LC1) ICI Resistance (LBA53).

This work is part of the innovative Marseille Immunopôle (@Immunopole) collaboration between academia and industry in the South of France.

Back in 2016, BSB attended a scientific seminar in honor of the 40th anniversary of the Centre d’Immunologie de Marseille-Luminy (CIML), one of the academic partners and since then we’ve been following many of the innovative immuno-oncology companies such as Innate Pharma, HalioDx, and ImCheck Therapeutics, who form part of this biotech cluster.

Marseille, home to innovative @immunopôle cluster

Professor Fabrice Barlesi is now Medical Director at Gustave Roussy (link) and kindly took time out of his busy schedule to speak to BSB about the PIONeeR project.

Perhaps not surprisingly, finding out exactly why some people respond to checkpoint inhibitors in NSCLC and others do not is not quite as simple as it sounds.

To learn more from our oncology analysis and obtain insights and commentary from our coverage of the ESMO20 virtual congress, subscribers can log-in or you can click here to purchase access to BSB Premium Content.

This content is restricted to subscribers

It’s a Bank Holiday weekend on both sides of the pond, which is always a good excuse for some shorter snippets as everyone will be enjoying the break outside, weather permitting!

In our latest Preview series, we address some pertinent questions that have come in from BSB readers on several topics in between AACR and ASCO, including tumour mutation burden (TMB), the PACIFIC trial, monalizumab, renal cell carcinoma (RCC) and castrate resistant prostate cancer (CRPC).

To learn more and get a heads up on our latest oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Free Email Updates
Subscribe to new post alerts, offers, and additional content!
We respect your privacy and do not sell emails. Unsubscribe at any time.
error: Content is protected !!